¿Beneficio o riesgo del uso de ácido ursodeoxicólico en prevención de cáncer colorrectal en pacientes con colangitis esclerosante primaria/colitis ulcerosa? / Benefit or risk from the use of ursodeoxycholic acid in prevention of colorectal
Pérez J., Tamara; Segovia M., Roberto; Quera P., Rodrigo.
Gastroenterol. latinoam
; 24(4): 185-190, 2013.
Artigo
em Espanhol
| LILACS | ID: lil-765137
cancer in patients with primary sclerosing cholangitis/ulcerative colitis? Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of intra-and extrahepatic bile ducts. About 70 percent of patients with CEP have idiopathic ulcerative colitis (IUC). PSC is considered a premalignant condition with an increased risk of colorectal cancer (CC). Individuals with PSC and IUC have higher risk of developing CC than IUC patients. There are different positions between American and European experts in the fields of hepatology and inflammatory bowel disease regarding the use of ursodeoxycholic acid (UDCA) in PSC and IUC as a chemo preventive. Studies have shown mixed results about the use of UDCA in preventing CC. The following is an update on the role of UDCA as a chemo preventive in this group of patients.
Biblioteca responsável:
CL1.1
Texto completo
Documentos relacionados